The primary aim of this work is to develop a quick, sensitive, and selective RP-HPLC method with straightforward extraction processes, minimal solvent and biological fluid use, and a rapid turnaround time. We have developed and validated an RP-HPLC method for estimating Empagliflozin and Linagliptin in human plasma. Using an Agilent C18 column (50μm, 4.6×250 mm) as the stationary phase, with a mobile phase of methanol and 0.1% ortho phosphoric acid in water (45:55, pH 2.5) at a 0.7 mL/min flow rate, and DAD detection at 248 nm, the method proved effective. It showed linearity over a concentration range of 10-50 µg/mL for Empagliflozin and 5-25 µg/mL for Linagliptin, with retention times of 4.186 min and 6.532 min, respectively. The method's specificity, precision, accuracy, and robustness were confirmed according to ICH guidelines. The limits of quantification (LOQ) were 0.45 µg/mL for Empagliflozin and 0.31 µg/mL for Linagliptin, while the limits of detection (LOD) were 0.15 µg/mL and 0.10 µg/mL, respectively. Stability tests showed the drugs remained stable through three freeze-thaw cycles. This RP-HPLC method is simple, reliable, precise, accurate, sensitive, and selective, making it suitable for routine quantitative analysis in pharmaceutical dosage forms, as well as for therapeutic drug monitoring, bioequivalence, bioavailability, pharmacokinetic, and toxicology studies of antidiabetic drugs.